Atlas Trials

Ganzhou Hemay Pharmaceutical Co., Ltd

14 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Ganzhou Hemay Pharmaceutical Co., Ltd

RecordFirmDate
A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors (NCT07624864)Ganzhou Hemay Pharmaceutical Co., Ltd2026-07-15
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis (NCT07650942)Ganzhou Hemay Pharmaceutical Co., Ltd2026-06-01
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD (NCT07314242)Ganzhou Hemay Pharmaceutical Co., Ltd2026-01-01
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 (NCT07446816)Ganzhou Hemay Pharmaceutical Co., Ltd2025-12-03
Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (NCT06610890)Ganzhou Hemay Pharmaceutical Co., Ltd2024-12-12
Bioequivalence Test of Hemay005 Tablets (NCT06610903)Ganzhou Hemay Pharmaceutical Co., Ltd2024-09-15
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment (NCT06380153)Ganzhou Hemay Pharmaceutical Co., Ltd2024-05-07
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage (NCT06376474)Ganzhou Hemay Pharmaceutical Co., Ltd2024-04-28
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease (NCT06145893)Ganzhou Hemay Pharmaceutical Co., Ltd2023-11-13
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors (NCT05749432)Ganzhou Hemay Pharmaceutical Co., Ltd2023-03-20
A Study of Hemay005 in Adult With Atopic Dermatitis (NCT05769946)Ganzhou Hemay Pharmaceutical Co., Ltd2022-11-24
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis (NCT05486104)Ganzhou Hemay Pharmaceutical Co., Ltd2022-11-08
In Vivo Mass Balance Study of [14C]Hemay005 (NCT05468645)Ganzhou Hemay Pharmaceutical Co., Ltd2022-07-25

Track Ganzhou Hemay Pharmaceutical Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.